RTP Mobile Logo
Select Publications

Ades L et al. Phase II study of pevonedistat (P) + azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (LB AML) (NCT02610777). ASCO 2020. Abstract 7506.

Challen GA, Goodell MA. Clonal hematopoiesis: Mechanisms driving dominance of stem cell clones. Blood 2020;136(14);1590-98. Abstract

Fenaux P et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med 2020;382(2):140-51. Abstract

Gallì A et al. Relationship between clone metrics and clinical outcome in clonal cytopenia. Blood 2021;138(11):965-76. Abstract

Garcia JS et al. Safety, efficacy, and patient-reported outcomes of venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: A Phase 1b study. ASH 2020;Abstract 656.

Myeloma/amyloidosis: Therapy, excluding transplantation; Novel approaches for relapsed/refractory myeloma and amyloidosis. ASH 2020. Abstract 653

Nazha A et al. Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Leukemia 2016;30(11):2214-20. Abstract

Pagliuca S et al. Molecular targeted therapy in myelodysplastic syndromes: New options for tailored treatments. Cancers 2021;13(4):784. Abstract

Ramsey HE et al. Oral azacitidine and cedazuridine approximate parenteral azacitidine efficacy in murine model. Targeted Oncol 2020;15(2):231-40. Abstract

Sallman DA et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results. ASCO 2020;Abstract 7507.

Savona MR et al. Clinical efficacy and safety of oral decitabine/cedazuridine in 133 patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Blood 2020;136:37-8. Abstract

Sekeres MA et al. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. Leukemia 2021;35(7):2119-24. Abstract